|
OMB APPROVAL |
OMB Number: 3235-0060 |
Expires: April 30, 2009 |
Estimated average burden hours per response: 38 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): August 25, 2006
Viropro, Inc.
(Exact Name of Registrant as Specified in its Charter)
| | |
Nevada | 333-06718 | 13-3124057 |
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| | |
8515, Place Devonshire, Suite 207 Montreal, Quebec, Canada | | H4P 2K1 |
(Address of principal executive offices) | | (Zip Code) |
Registrant's telephone number, including area code:(514) 731-8776
N/A
(Former Name or Former Address if Changed Since Last Report)
Check the appropriate box below if the Form 8K fining is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ]
Written communications pursuant to Rule 425 under the Securities Act (17CFR230.425)
[ ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a-12)
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ]
Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
SEC 873 (5-06)
Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
.
ITEM 4.02
NON-RELIANCE ON PREVIOUSLY ISSUED FINANCIAL STATEMENTS
The Company discloses today that the results issued for the quarter ended February 28th, 2006 can no longer be relied upon. The Company determined that its January 2006 transactions with Immuno Japan, Inc. and others were not properly recorded. As a result, deferred stock compensation will increase by approximately $991,000, intangible assets will increase by approximately $1,041,000, non-cash stock compensation will increase by approximately $140,000, and shareholders’ equity will increase by approximately $2,178,000. The Company's net loss for the quarter ended February 28, 2006 will increase to approximately $362,000 or $0.02 per share.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.
Date: August 25, 2006
VIROPRO, INC.
/s/ Jean-Marie Dupuy
Jean-Marie Dupuy, President and Chief Executive Officer
